Study Confirms Benefits of Lecanemab in Early Alzheimer Disease
Lecanemab is a humanized monoclonal antibody that works by selectively binding to, neutralizing and eliminating soluble toxic amyloid beta aggregates.
Diagnosis & Disease Information
Daily Multivitamin Improves Cognition in Older Adults, Says Large Study
The COSMOS-Mind study included 2262 participants and evaluated the effects of cocoa extract and multivitamin-mineral supplementation on cognitive function.
Noradrenergic Drugs Improve Cognition, Apathy in Alzheimer Disease
Researchers sought to evaluate the efficacy of noradrenergic drugs in the improvement of neuropsychiatric and cognitive symptoms in individuals with AD.
Identifying Risk Factors for Alzheimer Disease: Are They Modifiable?
Ines Moreno-Gonzalez, PhD, an adjunct associate professor of neurology, explains healthy aging can help reduce lifestyle risk factors for Alzheimer disease.
FDA Panel Votes on Pimavanserin for Alzheimer Disease Psychosis
Although not bound by the committee’s recommendations, the Agency does take them into consideration when making decisions on approval.
Crenezumab Misses Endpoints in Autosomal-Dominant Alzheimer Disease Trial
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
Dementia Risk in Patients With Atrial Fibrillation Tied to Diabetes, Stroke
Researchers sought to assess the risk factors for dementia in older adults with atrial fibrillation.
Impact of Physical Activity on Risk for Disabling Dementia by Gender
In a large, prospective cohort study, researchers assessed the association between daily total physical activity and the risk of developing disabling dementia in the general Japanese population.
Childhood Trauma Tied to Dementia Symptoms in Former Football Players
Researchers sought to determine whether concussions and a history of playing football influenced a possible association between ACEs and poor neuropsychiatric health.
Immunotherapeutic Vaccine Candidate Fast Tracked for Alzheimer Disease
UB-311 is an immunotherapeutic vaccine candidate that targets toxic forms of aggregated amyloid beta in the brain.
- Loading...
Loading...
Next post in News
Loading... 
Loading...